Benitec Biopharma Inc.
$13.99
▼
-0.46%
2026-04-21 05:44:02
benitec.com
NCM: BNTC
Explore Benitec Biopharma Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$483.71 M
Current Price
$13.99
52W High / Low
$17.15 / $9.85
Stock P/E
—
Book Value
$5.47
Dividend Yield
—
ROCE
-42.71%
ROE
-33.5%
Face Value
—
EPS
$-1.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
19
Beta
0.12
Debt / Equity
0.53
Current Ratio
67.69
Quick Ratio
54.67
Forward P/E
-1.21
Price / Sales
—
Enterprise Value
$204.52 M
EV / EBITDA
-4.24
EV / Revenue
—
Rating
None
Target Price
$24.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Arvinas, Inc. | $10.81 | — | $703.57 M | — | -20.59% | -16.23% | $14.51 / $5.9 | $6.83 |
| 2. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
| 3. | Xencor, Inc. | $12.8 | — | $941.6 M | — | -22.77% | -14.07% | $18.69 / $6.92 | $8.84 |
| 4. | SpyGlass Pharma, Inc. | $24.52 | — | $833.66 M | — | -38.64% | -67.7% | $32.44 / $20.15 | $-44.85 |
| 5. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 6. | Tectonic Therapeutic, Inc. | $28.76 | — | $554.1 M | — | -33.43% | -37.82% | $36.03 / $14.39 | $13.41 |
| 7. | Matinas BioPharma Holdings, Inc. | $0.55 | — | $3.52 M | — | -202.13% | -1.67% | $3.09 / $0.48 | $1.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -13.38 M | -9.8 M | -17.18 M | -10.19 M | -10.8 M | — |
| Net Profit | -11.84 M | -8.96 M | -16.15 M | -9.35 M | -9.55 M | — |
| EPS in Rs | -0.35 | -0.26 | -0.47 | -0.27 | -0.28 | -0.18 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0.07 M | 0.07 M |
| Operating Profit | -41.77 M | -22.49 M | -19.08 M | -17.85 M |
| Net Profit | -37.92 M | -21.75 M | -19.56 M | -18.21 M |
| EPS in Rs | -1.11 | -0.63 | -0.57 | -0.53 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 99.59 M | 52.21 M | 4.46 M | 5.97 M |
| Total Liabilities | 2.3 M | 4.96 M | 4.26 M | 3.09 M |
| Equity | 97.3 M | 47.25 M | 0.2 M | 2.88 M |
| Current Assets | 98.52 M | 51.67 M | 3.73 M | 4.82 M |
| Current Liabilities | 1.8 M | 4.92 M | 3.98 M | 2.53 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.59 M | -19.4 M | -18.01 M | -15.9 M |
| Investing CF | -0.02 M | -0.18 M | -0 M | -0.01 M |
| Financing CF | 70.48 M | 68.03 M | 16.02 M | 0 M |
| Free CF | -23.61 M | -19.58 M | -18.01 M | -15.91 M |
| Capex | -0.02 M | -0.18 M | -0 M | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | 2.74% | — | — |
| Earnings Growth % | -11.19% | -7.44% | — | — |
| Profit Margin % | — | -26082.67% | -24942.47% | — |
| Operating Margin % | — | -25441.33% | -24457.53% | — |
| Gross Margin % | — | 100% | 87.67% | — |
| EBITDA Margin % | — | -24933.33% | -24361.64% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-07-26 | 1:0.0588235 |